Abstract
Brain natriuretic peptide (BNP) release is a marker of increased myocardial wall tension,
which is elevated in patients with disturbed left ventricular function. As it is increasingly
being used as a reliable marker for diagnosis, optimization of pharmacological treatment,
and risk stratification, BNP measurement might be also relevant for patients undergoing
cardiac surgery. Measured BNP levels can be used to predict postoperative complications
and the risk of further cardiac events. Preoperative BNP levels support the decision
for the timing of aortic valve replacement in asymptomatic severe aortic stenosis.
An increase in BNP levels early predicts allograft rejection after cardiac transplantation
or ineffective cardiac resynchronization therapy. Moreover, BNP levels can be used
to differentiate between cardiac and non-cardiac reasons for acute dyspnea in the
management of surgical patients. Finally, the application of recombinant human BNP
seems to improve recovery after cardiac surgical procedures.
Thus, BNP can be a helpful tool for monitoring and treating patients before, during,
and after cardiac surgery to predict and improve the effectiveness of therapy and
reduce hospitalization and costs.
Key words
Brain natriuretic peptide - heart failure - cardiac surgery - heart transplantation
- cardiac resynchronization therapy
References
- 1
Sudoh T, Kangawa K, Minamino N, Matsuo H.
A new natriuretic peptide in porcine brain.
Nature.
1988;
332
78-81
- 2
Yasue H, Yoshimura M, Sumida H. et al .
Localization and mechanism of secretion of B-type natriuretic peptide in comparison
with those of A-type natriuretic peptide in normal subjects and patients with heart
failure.
Circulation.
1994;
90
195-203
- 3
DeLemos J A, McGuire D K, Drazner M H.
B-type natriuretic peptide in cardiovascular disease.
Lancet.
2003;
362
316-322
- 4
Levin E R, Gardner D G, Samson W K.
Natriuretic peptides.
N Engl J Med.
1998;
339
321-328
- 5
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M.
Plasma brain natriuretic peptide as a biochemical marker of high left ventricular
end-diastolic pressure in patients with symptomatic left ventricular dysfunction.
Am Heart J.
1998;
135
825-832
- 6
Cao L, Gardner D G.
Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts.
Hypertension.
1995;
25
227-234
- 7
Tamura N, Ogawa Y, Chusho H. et al .
Cardiac fibrosis in mice lacking brain natriuretic peptide.
PNAS.
2000;
97
4239-4244
- 8
Fischer Y, Filzmaier K, Stiegler H. et al .
Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic
peptide.
Clin Chem.
2001;
47
591-594
- 9
Maisel A S, Koon J, Krishnaswamy P. et al .
Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients
undergoing echocardiography to determine left ventricular dysfunction.
Am Heart J.
2001;
141
367-374
- 10
McDonagh T A, Robb S D, Morton J J. et al .
Biochemical detection of left-ventricular systolic dysfunction.
Lancet.
1998;
351
9-13
- 11
Wieczorek S J, Wu A H, Christenson R. et al .
A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction
and heart failure: a multicenter evaluation.
Am Heart J.
2002;
144
834-839
- 12
Lubien E, DeMaria A, Krishnaswamy P. et al .
Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with
Doppler velocity recordings.
Circulation.
2002;
105
595-601
- 13
Troughton R W, Prior D L, Pereira J J. et al .
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of
left ventricular diastolic function and right ventricular systolic function.
J Am Coll Cardiol.
2004;
43
416-422
- 14
Redfield M M, Rodeheffer R J, Jacobsen S J. et al .
Plasma brain natriuretic peptide concentration: impact of age and gender.
J Am Coll Cardiol.
2002;
40
976-982
- 15
McCullough P A, Duc P, Omland T. et al .
B -type natriuretic peptide and renal function in the diagnosis of heart failure:
an analysis from the Breathing Not Properly Multinational Study.
Am J Kidney Dis.
2003;
41
571-579
- 16
Wang T J, Larson M G, Levy D. et al .
Impact of obesity on plasma natriuretic peptide levels.
Circulation.
2004;
109
594-600
- 17
McNairy M, Gardetto N, Clopton P. et al .
Stability of B-type natriuretic peptide levels during exercise in patients with congestive
heart failure: implications for outpatient monitoring with B-type natriuretic peptide.
Am Heart J.
2002;
143
406-411
- 18
Pfister R, Scholz M, Wielckens K. et al .
Use of NT-proBNP in routine testing and comparison to BNP.
Eur J Heart Fail.
2004;
6
289-294
- 19
Collinson P O, Barnes S C, Gaze D C. et al .
Analytical performance of N terminal pro B type natriuretic peptide (NT-proBNP) assay
on the ElecsysTM 1010 and 2010 analysers.
Eur J Heart Fail.
2004;
6
365-368
- 20
Berendes E, Schmidt C, van Aken H. et al .
A-type and B-type natriuretic peptides in cardiac surgical procedures.
Anesth Analg.
2004;
98
11-19
- 21
Hutfless R, Kazanegra R, Madani M. et al .
Utility of B-type natriuretic peptide in predicting postoperative complications and
outcomes in patients undergoing heart surgery.
J Am Coll Cardiol.
2004;
43
1873-1879
- 22
Wazni O M, Martin D O, Marrouche N F. et al .
Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation
in patients undergoing cardiac surgery.
Circulation.
2004;
110
124-127
- 23
Avidan M S, Meehan N, Ponte J, El-Gamel A, Sherwood R A.
Changes in brain natriuretic peptide concentrations following open cardiac surgery
with cardioplegic cardiac arrest.
Clin Chim Acta.
2001;
303
127-132
- 24
Chello M, Mastroroberto P, Perticone F. et al .
Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of
left ventricular systolic function after coronary artery bypass.
Eur J Cardiothor Surg.
2001;
20
140-146
- 25
Watanabe M, Egi K, Hasegawa S. et al .
Significance of serum atrial and brain natriuretic peptide release after coronary
artery bypass grafting.
Surg Today.
2003;
33
671-673
- 26
Bergler-Klein J, Klaar U, Heger M. et al .
Natriuretic peptides predict symptom-free survival and postoperative outcome in severe
aortic stenosis.
Circulation.
2004;
109
2302-2308
- 27
Eimer M J, Ekery D L, Rigolin V H. et al .
Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation
and preserved left ventricular systolic function.
Am J Cardiol.
2004;
94
676-678
- 28
El Gamel A, Yonan N A, Keevil B. et al .
Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation.
Ann Thorac Surg.
1997;
63
1095-1100
- 29
Chin C, Akhtar M J, Rosenthal D N, Bernstein D.
Safety and utility of the routine surveillance biopsy in pediatric patients 2 years
after heart transplantation.
J Pediatr.
2000;
136
238-242
- 30
Masters R G, Davies R A, Veinot J P, Hendry P J, Smith S J, de Bold A J.
Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection
in humans.
Circulation.
1999;
100
287-291
- 31
Claudius I, Lan Y T, Chang R K, Wetzel G T, Alejos J.
Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac
allograft pathology in pediatric heart transplant recipients.
Am J Cardiol.
2003;
92
1368-1370
- 32
Auricchio A, Stellbrink C, Block M. et al .
The effect of pacing chamber and atrioventricular delay on acute systolic function
of paced patients with congestive heart failure.
Circulation.
1999;
99
2993-3001
- 33
Breithardt O A, Sinha A M, Schwammenthal E. et al .
Acute effects of cardiac resynchronization therapy on functional mitral regurgitation
in advanced systolic heart failure.
J Am Coll Cardiol.
2003;
41
765-770
- 34
Cazeau S, Leclercq C, Lavergne T. et al .
Multisite stimulation in cardiomyopathies (MUSTIC) study investigators. Effects of
multisite biventricular pacing in patients with heart failure and intraventricular
conduction delay.
N Engl J Med.
2001;
344
873-880
- 35
Abraham W T, Fisher W G, Smith A L. et al .
Cardiac resynchronization in chronic heart failure.
N Engl J Med.
2002;
346
1845-1853
- 36
Auricchio A, Stellbrink C, Sack S. et al .
Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy
in patients with heart failure and ventricular conduction delay.
J Am Coll Cardiol.
2002;
39
2026-2033
- 37
Stellbrink C, Breithardt O A, Franke A. et al .
Impact of cardiac resynchronization therapy using hemodynamically optimized pacing
on left ventricular remodeling in patients with congestive heart failure and ventricular
conduction disturbance.
J Am Coll Cardiol.
2001;
38
1957-1965
- 38
Sinha A M, Filzmaier K, Breithardt O A. et al .
Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy
of long-term cardiac resynchronization therapy in patients with heart failure.
Am J Cardiol.
2003;
91
755-758
- 39
Sinha A M, Filzmaier K, Kunz D. et al .
Correlation of brain natriuretic peptide release, cardiopulmonary exercise testing
and 6 minute walking test in patients with heart failure and cardiac resynchronization
therapy.
J Am Coll Cardiol.
2003;
41
60 (abstract)
- 40
Maisel A S, Krishnaswamy P, Nowak R M. et al .
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart
failure.
N Engl J Med.
2002;
347
161-167
- 41
Maisel A S, McCord J, Nowak R M. et al .
Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with
reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational
Study.
J Am Coll Cardiol.
2003;
41
2010-2017
- 42
Morrison L K, Harrison A, Krishnaswamy P. et al .
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart
failure from lung diseases in patients presenting with dyspnea.
J Am Coll Cardiol.
2002;
39
202-209
- 43
Mueller C, Scholer A, Laule-Kilian K. et al .
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.
N Engl J Med.
2004;
350
647-654
- 44
Goetze J P, Christoffersen C, Perko M. et al .
Increased cardiac BNP expression associated with myocardial ischemia.
FASEB.
2003;
17
1105-1107
- 45
Wiviott S D, Cannon C P, Morrow D A. et al .
Differential expression of cardiac biomarkers by gender in patients with unstable
angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 substudy.
Circulation.
2004;
109
580-586
- 46
De Lemos J A, Morrow D A, Bentley J H. et al .
The prognostic value of B-type natriuretic peptide in patients with acute coronary
syndromes.
N Engl J Med.
2001;
345
1014-1021
- 47
Morrow D A, de Lemos J A, Sabatine M S. et al .
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation
myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.
J Am Coll Cardiol.
2003;
41
1264-1272
- 48
Richards A M, Nicholls M G, Espiner E A. et al .
B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.
Circulation.
2003;
107
2786-2792
- 49
Kucher N, Printzen G, Goldhaber S Z.
Prognostic role of brain natriuretic peptide in acute pulmonary embolism.
Circulation.
2003;
107
2545-2547
- 50
Troughton R W, Frampton C M, Yandle T G. et al .
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide
(N-BNP) concentrations.
Lancet.
2000;
355
1126-1130
- 51
Tsutamoto T, Wada A, Maeda K. et al .
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular
remodeling in patients with congestive heart failure.
J Am Coll Cardiol.
2001;
37
1228-1233
- 52
Richards A M, Doughty R, Nicholls M G. et al .
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction.
Circulation.
1999;
99
786-792
- 53
Latini R, Masson S, Anand I. et al .
Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in
symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Circulation.
2002;
106
2454-2458
- 54
Wang T, Larson M G, Levy D. et al .
Plasma natriuretic peptide levels and the risk of cardiovascular event and death.
N Engl J Med.
2004;
350
655-663
- 55
Colucci W S, Elkayam U, Horton D P. et al .
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive
heart failure. Nesiritide Study Group.
N Engl J Med.
2000;
343
246-253
- 56
Publication Committee for the VMAC Investigators (Vasodilatation in the Management
of Acute CHF) .
Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive
heart failure: a randomized controlled trial.
JAMA.
2002;
287
1531-1540
- 57
Moazami N, Damiano R J, Bailey M S. et al .
Nesiritide (BNP) in the management of postoperative cardiac patients.
Ann Thorac Surg.
2003;
75
1974-1976
- 58
De Denus S, Pharand C, Williamson D R.
Brain natriuretic peptide in the management of heart failure.
Chest.
2004;
125
652-668
Dr. Dr. Anil-Martin Sinha
II. Medizinische Klinik
Klinikum Coburg GmbH
Ketschendorfer Straße 33
96450 Coburg
Germany
Phone: + 499561220
Fax: + 49 95 61 22 72 20
Email: amsinha@gmx.de
